AmyriAD acquires AD04 Alzheimer's program from ADvantage
AmyriAD announced the acquisition of the AD04 program, a Phase 2b-ready investigational drug targeting neuroinflammation in mild Alzheimer's disease. The program was derived from a 332-patient Phase 2 vaccine study and is planned to enter Phase 2b development under the Innovative Licensing and Access Pathway.
Primary source
Company press release (PR Newswire), November 16, 2026
AmyriAD Therapeutics Acquires AD04 Alzheimer's Program from ADvantage, Further Expanding Its Clinical-Stage Cognition Pipeline
Machine-summarized from the source above; not independently reported. How we use automation